FDA Approves Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder

Article Link: FDA Approves Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder

South San Francisco, CA — August 14, 2020 — Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for adults…

Source: FDA New Drug Approvals